Moderna, Inc.
MRNA
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3ā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$28.02
Price+4.98%
$1.33
1Y
Price
Market Cap
$10.902b
Large
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-535.2%
EBITDA Margin-581.0%
Net Profit Margin-642.2%
Free Cash Flow MarginRevenue
$3.060b
-4.3%
1y CAGR-40.4%
3y CAGR-28.7%
5y CAGREarnings
-$2.903b
+18.5%
1y CAGR-37.8%
3y CAGR-36.2%
5y CAGREPS
-$7.53
+18.8%
1y CAGR-39.2%
3y CAGR-36.7%
5y CAGRBook Value
$9.399b
$12.010b
Assets$2.611b
Liabilities$698m
DebtDebt to Assets
5.8%
-0.3x
Debt to EBITDAFree Cash Flow
-$3.490b
+13.9%
1y CAGR-58.5%
3y CAGR-60.3%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company